About our company

ABOUT US

Transforming healthcare through precision medicine.

Velsera’s vision is to be the discovery, evidence generation, and clinical delivery platform for precision medicine. We help doctors and drug hunters make better decisions about providing the right therapy to the right patients at the right time.  We have spent the last 10+ years’ developing industry leading clinical software, knowledge and perspectives on genetic disease - including oncology, rare and hereditary diseases.

Velsera was formed in January 2023 through the merger of three leading precision medicine companies – Perian Dx in the clinical diagnostics space, Seven Bridges in the life science analytics domain and UgenTec in the clinical laboratory automation industry. Today, Velsera employs 600 people across US, Europe and Asia, including over 150 employees with MD/PhD across our own in-house scientific, bioinformatic and clinical expert teams.

Our customer base includes some of the largest and most prestigious biopharma/biotech companies; government agencies and non-profits; clinical institutions and AMCs; diagnostic lab groups; we have partnerships with OEM lab instrument providers and also partner with diagnostic assay developers. The combination of our founding companies has created a unique capability and solution set to serve these customers across the diagnostic and drug development and commercialization life-cycle, including – (sub)population health, drug discovery, clinical development of new diagnostics and therapeutics, clinical delivery, lab management, RWD/E.

PURPOSE

Powering precision medicine.

Velsera connects healthcare and life sciences to reveal the true promise of precision medicine—a continuous flow of knowledge between researchers, scientists and clinicians around the world, creating insights that radically improve human health.

We power this ecosystem of insight with data made actionable by AI and technology solutions that accelerate R&D, democratize omics and provide bedside analytics to improve patient outcomes.

Stay in the loop with product and service updates as we create a new era of medicine powered by Velsera—the precision engine company.

Our Leadership

Executive team.

Jamie Littlejohns

Chief Executive Officer

Jamie joined Velsera in January 2024, having previously provided external support to Velsera and their founding business since early 2022. He has worked in healthcare and life sciences since 2010 and previously was a Partner at McKinsey & Company where he spent over a decade and led their Health & Life Science Investing Practice in Europe, specializing in supporting investor-backed health & life science tech businesses on their scale-up journeys.

Nathan Baird

Chief Product Officer

Nate has deep experience in product portfolio strategy, financial analysis and next-generation sequencing product development, as well as an extensive academic research background in molecular genetics and genomics. Prior to joining Velsera, he worked at Illumina for more than eight years.

Guy Emslie

Chief Financial Officer

Guy Emslie is the Chief Financial Officer at Velsera, bringing over 15 years of financial leadership experience in scaling technology-driven businesses. With a strong background in enterprise software, SaaS, and tech services, Guy has a proven track record of driving financial strategy and growth in dynamic, high-tech environments.

Jim Lee

Chief Commercial Officer

Jim is a passionate commercial officer with extensive experience in the life sciences sector, dedicated to driving advancements in patient care. Adept leader in operations and revenue generation within the dynamic and competitive life sciences industry. He has worked in healthcare and life sciences since 2008 and was Vice President of Sales at Clarivate where he spent over a decade and led their Health & Life Science Commercial Group globally, specializing in scaling customer facing teams.

John Patrick

Chief Technology Officer

JP brings extensive experience in product development, software engineering and secure cloud hosting to Velsera. Most recently, he was the EVP of engineering at TalentReef, and beforehand he was the SVP of product development and cloud hosting services at Bioclinica.

Untitled (1200 x 1750 px) (1200 x 1750 px) (1200 x 1500 px)

Julie Furt

Chief Customer Officer

Julie has extensive experience managing high-growth, high-performing global customer success teams and has worked with clients across a variety of industries, including life sciences, healthcare, and government. She has particular interest in nurturing partnerships with clients, customer success management, and customer value realization.

Value loop

How we accelerate the value of omics.

When knowledge flows freely between the clinical realm and R&D, a network effect arises: research discoveries translate to diagnostics, and patient outcomes inform new breakthroughs.

This virtuous cycle drives what we call the value loop—iterative learning and technology-enabled solutions that support all points in the healthcare continuum.

Sample

Our technology manages and orchestrates the flow of patient samples using cutting-edge tracking and tracing to guard the quality of data and maximize its use for research and diagnostics.

Analyze

We apply AI and machine learning software to automate the analysis of multiple testing modalities, producing results that are qualitative, accurate and amenable for clinical annotation and reporting.

Annotate

We equip clinicians with annotation that combines multi-omic data, clinical analytics and treatment guidelines to reveal relevant information for diagnosis, therapy options and response prediction.

Report

Our teams curate a continuously growing knowledge base that effectively democratizes omics, providing unparalleled access to data and clinical information for accurate and up-to-date reporting.

Aggregate

We aggregate clinical information and its underlying raw data to provide a multi-omic view that enhances data from clinical trials and research studies, leveraging insight from both sides of the loop.

Integrate

Our broad expertise integrating diverse datasets provides the tools and services needed to make data work together, unlocking unprecedented insights that make joint discovery possible.

Explore

Our data and knowledge bases can be accessed independently or in conjunction with Velsera experts, with AI and machine learning performing intelligent, deep analyses that yield actionable insights.

Generalize

These data-driven insights drive precision R&D, improve drug discovery and clinical trials as well as inform routine diagnostics— closing the loop and setting the standard for omics-based healthcare.